Theragent, a cell therapy contract development and management organization (CDMO) focused on advancing next-generation cancer and rare disease treatments, signed a multi-year exclusive contract with Insight68, an AI-driven software provider that aims to digitalize and streamline the cell therapy manufacturing process. The partnership bolsters Theragent’s commitment to 100% digital batch record compliance. “Theragent set out from the beginning with a mission to be completely paperl...